Tumor lysis syndrome in extensive-stage small-cell lung cancer.
Tumor lysis syndrome is a constellation of metabolic complications that occurs in the setting of treatment of hematologic malignancies. On occasion, it has been reported to occur after therapy for solid tumors associated with large tumor burdens and aggressive therapy. We herein report the rare occurrence of acute tumor lysis syndrome in a woman with extensive-stage small-cell lung cancer after cytotoxic therapy.
Beriwal
Sushil
S
Department of Radiation Oncology, MS 200, Hahnemann University Hospital, Broad and Vine Street, Philadelphia, PA 19102, USA.
Singh
Shailender
S
Garcia-Young
Jorge A
JA
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000556:secondary; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019772:Topotecan / Q000009:adverse effects* / Q000627:therapeutic use; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019772:Topotecan